All In Biotech

Drug Trial Radar · NCT02196506

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Last checked: Nov 20, 2026Latest source record: Aug 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 837 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

837

Actual

Start

Jul 2014

Primary completion

Apr 2016

Study completion May 2016

Sponsor

Sponsor type
Industry
Collaborators
H. Lundbeck A/S
First posted
Jul 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress

Conditions

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders

Interventions

  • Placebo + ADTDrug

    Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)

  • Brexpiprazole +ADTDrug

    Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Montgomery-Asberg DepressionTime frame: From baseline (end of Phase A [Week 8]) to week 14

Locations

47 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Beverly Hills, California

  • Site not named

    Denver, Colorado

  • Site not named

    Hialeah, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Alpharetta, Georgia

  • Site not named

    Smyrna, Georgia

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Rochester Hills, Michigan

  • Site not named

    Cherry Hill, New Jersey

  • Site not named

    Jamaica, New York

  • Site not named

    New York, New York

  • Site not named

    Staten Island, New York

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Edmond, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Salem, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Lincoln, Rhode Island

  • Site not named

    Columbia, South Carolina

  • Site not named

    Memphis, Tennessee

  • Site not named

    Wichita Falls, Texas

  • Site not named

    Murray, Utah

  • Site not named

    Woodstock, Vermont

  • Site not named

    Charlottesville, Virginia

  • Site not named

    Richmond, Virginia

  • Site not named

    Seattle, Washington

  • Site not named

    Spokane, Washington

  • Site not named

    Achim, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Düsseldorf, Germany

  • Site not named

    Frankfurt, Germany

  • Site not named

    Freiburg im Breisgau, Germany

  • Site not named

    Oranienburg, Germany

  • Site not named

    Stralsund, Germany

  • Site not named

    Würzburg, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Győr, Hungary

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.